The company plans to use the financing to advance TT-20, its lead drug candidate for the treatment of white matter brain injury in preterm infants, according to a Dec. 13 Tellus news release.
Perceptive Xontogeny Venture Fund led the series A financing round and the company’s earlier seed round.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
